Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
Highly active antiretroviral therapy (HAART) has improved the long time survival of HIV
infected individuals. However an increasing number of HIV-patients have developed metabolic
and morphological alterations including peripheral lipoatrophy.
The main hypothesis of the study is that switching from thymidine-analogue based HAART will
reverse lipoatrophy.
We plan to perform an observational study recruiting up to 100 HIV-infected patients
receiving Trizivir (zidovudine/lamivudine/abacavir).
The patients will be offered an NRTI or lopinavir/ritonavir instead of zidovudine or they can
choose to continue with Trizivir.
The main endpoint is changes in peripheral fat mass as determined by DEXA-scanning.
Phase:
Phase 4
Details
Lead Sponsor:
Danish HIV Research Group
Collaborators:
Aarhus University Hospital Hvidovre University Hospital Odense University Hospital Rigshospitalet, Denmark